Hoylu AB
22.2.2021 07:15:34 CET | Globenewswire | Press release
Stockholm, Sweden, February 19, 2021 – Hoylu, a leader in visual collaboration solutions for distributed teams, announced today that it has received a new order from Walbridge (https://www.walbridge.com/about/company-overview/) a full-service construction firm headquartered in Detroit, MI, to use Hoylu’s workspace and pull planning software (https://www.hoylu.com/pull-planning/) for a new large infrastructure project at the border between the US and Canada.
Walbridge is an existing customer of Hoylu and the new order value is SEK 375,000, including software licenses (SEK 100,000 ARR) and a 3 channel HoyluWall (https://www.hoylu.com/hoyluwall/) .
For more information, please contact:
Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com
Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com
About Hoylu
Hoylu’s mission is to make remote work and information sharing easy. Hoylu’s Connected Workspaces™ help enterprise clients manage activities, visualize work and motivate people to perform their best by avoiding miscommunication and secure success. For more information: www.hoylu.com
Test Hoylu for free: https://www.hoylu.com/signup/
Ticker symbol: Hoylu
Marketplace: Nasdaq First North Growth Market
Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550, ca@mangold.se
Publication
The information was submitted for publication, through the agency of the contact persons set out above on February 19, 2021 at 8:45 CET.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
